Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Editas Medicine Inc shares valued at $12,757 were sold by Burkly Linda on Jul 31 ’25. At $2.49 per share, Burkly Linda sold 5,121 shares. The insider’s holdings dropped to 64,398 shares worth approximately $0.16 million following the completion of this transaction.
Also, Burkly Linda purchased 7,500 shares, netting a total of over 25,950 in proceeds.
Before that, Parison Amy had sold 446 shares from its account. In a trade valued at $769, the SVP, Chief Financial Officer traded Editas Medicine Inc shares for $1.72 each. Upon closing the transaction, the insider’s holdings decreased to 446 shares, worth approximately $43589.94.
As published in their initiating research note from H.C. Wainwright on April 28, 2025, Editas Medicine Inc [EDIT] has been a Buy and the price target has been revised to $3. Analysts at JP Morgan downgraded the stock from ‘”a Neutral”‘ to ‘”an Underweight”‘ outlook in a report released in mid December. As of December 13, 2024, Truist has decreased its “Buy” rating to a “Hold” for EDIT. Earlier on December 13, 2024, Stifel downgraded its rating. Their new recommendation was “a Hold” for EDIT stock which previously was a “a Buy”.
Analyzing EDIT Stock Performance
On last trading session, Editas Medicine Inc [NASDAQ: EDIT] plunged -1.58% to $2.49. The stock’s lowest price that day was $2.4501, but it reached a high of $2.58 in the same session. During the last five days, there has been a drop of approximately -0.80%. Over the course of the year, Editas Medicine Inc shares have dropped approximately -47.36%.
Is Editas Medicine Inc subject to short interest?
Stocks of Editas Medicine Inc saw a sharp rise in short interest on 2025-07-15 jumping by 89826.0 shares to 8.52 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 8.43 million shares. A jump of 1.05% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.57 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.57.
Which companies own the most shares of Editas Medicine Inc (EDIT)?
In terms of Editas Medicine Inc share price expectations, FactSet research, analysts set an average price target of 12 in the next 12 months, up nearly 374.31% from the previous closing price of $2.53. Analysts anticipate Editas Medicine Inc stock to reach 35 by 2025, with the lowest price target being 5. In spite of this, 9 analysts ranked Editas Medicine Inc stock as Buy at the end of 2025.
